{"id":390662,"date":"2018-06-04T00:00:00","date_gmt":"2018-06-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocv0007-2018-biopharma-atrial-fibrillation-treatment-algorithms-claims-data-analysis-us-2018\/"},"modified":"2026-05-06T11:23:26","modified_gmt":"2026-05-06T11:23:26","slug":"algocv0007-2018-biopharma-atrial-fibrillation-treatment-algorithms-claims-data-analysis-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocv0007-2018-biopharma-atrial-fibrillation-treatment-algorithms-claims-data-analysis-us-2018\/","title":{"rendered":"Atrial Fibrillation | Treatment Algorithms | Claims Data Analysis | US | 2018"},"content":{"rendered":"<p>For the estimated 5 million people in the United States with atrial fibrillation (<abbr data-original-title=\"atrial fibrillation\" title=\"\">AF<\/abbr>), several treatment approaches can be used, each of which has\u00a0a wide range of pharmacological options. Guidelines from the American Heart Association, American College of Cardiology Foundation, and Heart Rhythm Society\u00a0recommend the implementation of rate control therapy to control heart rate and\u00a0rhythm control treatment to establish a normal sinus rhythm for appropriate patients. The use of rate and\/or rhythm control is often accompanied by antithrombotic therapies to reduce the risk of stroke\u00a0in at-risk patients. This report provides quantitative analysis of treatment patterns, patient share by line of therapy, progression between lines, duration of treatment on each line, and use of concomitant treatment.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>What patient shares do key therapies and drug classes command by line of therapy in newly diagnosed\u00a0<abbr data-original-title=\"atrial fibrillation\" title=\"\">AF<\/abbr>\u00a0patients?<\/li>\n<li>What proportion of\u00a0<abbr data-original-title=\"atrial fibrillation\" title=\"\">AF<\/abbr>\u00a0patients receive drug treatment within 720 days of initial diagnosis? How many progress to second\u00a0or third lines of treatment within 720 days?<\/li>\n<li>How have the direct\u00a0<abbr data-original-title=\"Factor X activated\" title=\"\">FXa<\/abbr>\u00a0inhibitors been integrated into the\u00a0<abbr data-original-title=\"atrial fibrillation\" title=\"\">AF<\/abbr>\u00a0treatment algorithm, and to what extent have they displaced warfarin?<\/li>\n<li>Does Eliquis\u00a0or\u00a0Xarelto\u00a0command\u00a0a\u00a0greater\u00a0patient share, and uptake of which drug is growing at the fastest pace?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated\u00a0<abbr data-original-title=\"atrial fibrillation\" title=\"\">AF<\/abbr>patients<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis\u00a0<\/em>provides detailed analysis of brand use across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.<\/p>\n<p><strong>Markets covered:<\/strong>\u00a0United States<\/p>\n<p><strong>Real-world data:\u00a0<\/strong>Longitudinal patient-level claims data analysis<\/p>\n<p><strong>Key companies:\u00a0<\/strong>Bayer, Bristol-Myers Squibb, Pfizer, Daiichi Sankyo, Boehringer Ingelheim<\/p>\n<p><strong>Key drugs:\u00a0<\/strong>Xarelto, Eliquis, Savaysa, Pradaxa, Warfarin<\/p>\n<p><strong>Key analysis provided:<\/strong><\/p>\n<ul>\n<li>Brand use across longitudinal patient sample.<\/li>\n<li>Newly diagnosed patient analysis.<\/li>\n<li>Treatment initiation and progression.<\/li>\n<li>Line of therapy analysis.<\/li>\n<li>Combination therapy analysis.<\/li>\n<li>Source of business for recently treated patients.<\/li>\n<li>Persistency and compliance analysis.<\/li>\n<li>Product-level patient flowcharts.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390662","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-atrial-fibrillation","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390662\/revisions"}],"predecessor-version":[{"id":393786,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390662\/revisions\/393786"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}